8月18日，强生盘中上涨3.15%，报268.66美元/股，成交额2.77亿美元。近期多重利好持续催化股价走强。
消息面上，Guggenheim于8月6日将强生目标价从270美元上调至287美元并维持买入评级，富国银行此前亦将目标价从272美元上调至282美元，Argus Research更将目标价提升至300美元。与此同时，公司7月28日宣布以55亿美元和解滑石粉诉讼，有效消除长期法律不确定性；旗下Rybrevant Faspro获FDA优先审评用于头颈癌治疗，审查周期缩短至6个月；公司还获得以25.8亿美元收购Sail Biomedicines的独家选择权，推进体内CAR-T平台布局。多重利好叠加推动股价突破前期平台。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.